// App-Quantinova.ai

S168 : SABATOLIMAB PLUS HYPOMETHYLATING AGENTS (HMAS) IN PATIENTS (PTS) WITH HIGH-/VERY HIGH-RISK MYELODYSPLASTIC SYNDROME (HR/VHR-MDS) AND ACUTE MYELOID LEUKEMIA (AML): SUBGROUP ANALYSIS OF A PHASE 1 STUDY

Researchers

Presenter

  • Andrew Wei

Principal Investigators

  • Kimmo Porkka

  • Steve Knapper

  • Elie Traer

  • Sebastian Scholl

  • Guillermo Garcia-Manero

  • Norbert Vey

  • Martin Wermke

  • Jeroen Janssen

  • Rupa Narayan

  • Sun Loo

  • Natalia Tovar

  • Mika Kontro

  • Oliver Ottmann

  • Purushotham Naidu

  • Sema Kurtulus

  • Elena Orlando

  • Nidhi Patel

  • Jessica Makofske

  • Fei Ma

  • Na Zhang

  • Anisa Mohammed

  • Mikael L. Rinne

  • Uma Borate

  • Andrew M. Brunner

Medical Centers

  • Massachusetts General Hospital, Boston, MA, United States

  • Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland.

  • Science University, Portland, Oregon, United States

  • Amsterdam University Medical Center - Amsterdam - Netherlands (The)

  • The Alfred Hospital, Melbourne, Australia

  • Novartis Institute for Biomedical Research, Cambridge, MA, United States

  • Cardiff University, Cardiff, United Kingdom

  • Novartis Pharmaceuticals Corporation East Hanover NJ United States

  • University Hospital Dresden, Dresden, Germany

  • The Alfred Hospital and Monash University, Melbourne, Australia

  • Institut Paoli-Calmettes, Marseille, France

  • 19Hospital Clínic Barcelona Spain

  • Oregon Health &amp

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Locations

  • United States

  • Finland

  • Netherlands

  • Australia

  • United Kingdom

  • Germany

  • France

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Alpha-thalassemia myelodysplasia syndrome

  • Acute myelocytic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Vidaza

  • Decitabine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT03066648

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved